The immunobiology of interleukin-27

Annual Review of Immunology

Volumn 33, Issue , 2015, Pages 417-443

  Yoshida, Hiroki ^a   Hunter, Christopher A ^b  

^a SAGA UNIVERSITY   (Japan)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

Author keywords

Autoimmunity; IL 10; IL 17; Infectious disease; Inflammation

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR; INTERLEUKIN 27P28; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; HUMAN; HUMORAL IMMUNITY; IMMUNOBIOLOGY; INFECTION; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; NEOPLASM; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; ADAPTIVE IMMUNITY; ANIMAL; CHEMISTRY; IMMUNITY; IMMUNOLOGY; INFLAMMATION; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; TRANSLATIONAL RESEARCH;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-27; T-LYMPHOCYTE SUBSETS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84927662065     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032414-112134     Document Type: Review

References (229)

1. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, et al. 2002. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 16:779-90
2. Pflanz S,Hibbert L, Mattson J, RosalesR, Vaisberg E, et al. 2004. WSX-1and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172:2225-31
3. Kastelein RA, Hunter CA, Cua DJ. 2007. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25:221-42
4. Nieuwenhuis EE, Neurath MF, Corazza N, Iijima H, Trgovcich J, et al. 2002. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. PNAS 99:16951-56
5. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, et al. 2000. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407:916-20
6. YoshidaH,Hamano S, SenaldiG, Covey T, Faggioni R, et al. 2001. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15:569-78
7. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, et al. 2003. Cutting Edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170:4886-90
8. Lucas S, Ghilardi N, Li J, de Sauvage FJ. 2003. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and-independent mechanisms. PNAS 100:15047-52
9. Villarino A, Hibbert L, Lieberman L,Wilson E, Mak T, et al. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19:645-55
10. Artis D, Johnson LM, Joyce K, Saris C, Villarino A, et al. 2004. Cutting Edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J. Immunol. 172:4672-75
11. Hamano S, Himeno K, Miyazaki Y, Ishii K, Yamanaka A, et al. 2003. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19:657-67
12. Artis D, Villarino A, Silverman M, He W, Thornton EM, et al. 2004. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 173:5626-34
13. Holscher C, Holscher A, Ruckerl D, Yoshimoto T, Yoshida H, et al. 2005. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J. Immunol. 174:3534-44
14. Rosas LE, Satoskar AA, Roth KM, Keiser TL, Barbi J, et al. 2006. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to Leishmania donovani infection but develop severe liver immunopathology. Am. J. Pathol. 168:158-69
15. Anderson CF, Stumhofer JS, Hunter CA, Sacks D. 2009. IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J. Immunol. 183:4619-27
16. Robinson CM, Nau GJ. 2008. Interleukin-12 and interleukin-27 regulate macrophage control of Mycobacterium tuberculosis. J. Infect. Dis. 198:359-66
17. de Aquino MT, Kapil P, Hinton DR, Phares TW, Puntambekar SS, et al. 2014. IL-27 limits central nervous system viral clearance by promoting IL-10 and enhances demyelination. J. Immunol. 193:285-94
18. Tirotta E, Duncker P, Oak J, Klaus S, Tsukamoto MR, et al. 2013. Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis. J. Neuroimmunol. 254:110-16
19. Sun J, Dodd H, Moser EK, Sharma R, Braciale TJ. 2011. CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat. Immunol. 12:327-34
20. Liu FD, Kenngott EE, Schroter MF, Kuhl A, Jennrich S, et al. 2014. Timed action of IL-27 protects from immunopathology while preserving defense in influenza. PLOS Pathog. 10:e1004110
21. Findlay EG, Greig R, Stumhofer JS, Hafalla JC, de Souza JB, et al. 2011. Essential role for IL-27 receptor signaling in prevention of Th1-mediated immunopathology during malaria infection. J. Immunol. 185:2482-92
22. Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N. 2008. Cutting Edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T Cells. J. Immunol. 180:2752-56
23. Yang J, Yang M, Htut TM, Ouyang X, Hanidu A, et al. 2008. Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORγt. Eur. J. Immunol. 38:1204-14
24. Shimizu S, Sugiyama N, Masutani K, Sadanaga A, Miyazaki Y, et al. 2005. Membranous glomerulonephritis developmentwithTh2-type immune deviations in MRL/lprmice deficient for IL-27 receptor (WSX-1). J. Immunol. 175:7185-92
25. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, et al. 2006. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7:929-36
26. Troy AE, Zaph C, Du Y, Taylor BC, Guild KJ, et al. 2009. IL-27 regulates homeostasis of the intestinal CD4+ effector T cell pool and limits intestinal inflammation in a murine model of colitis. J. Immunol. 183:2037-44
27. Igawa T, Nakashima H, Sadanaga A, Masutani K, Miyake K, et al. 2009. Deficiency in EBV-induced gene 3 (EBI3) in MRL/lpr mice results in pathological alteration of autoimmune glomerulonephritis and sialadenitis. Mod. Rheumatol. 19:33-41
28. Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. 2007. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol. 179:4415-23
29. Diveu C, McGeachyMJ, Boniface K, Stumhofer JS, SatheM, et al. 2009. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. 182:5748-56
30. Yamanaka A, Hamano S, MiyazakiY, Ishii K, Takeda A, et al. 2004. Hyperproduction of proinflammatory cytokines byWSX-1-deficient NKT cells in concanavalin A-induced hepatitis. J. Immunol. 172:3590-96
31. Zhang S, Liang R, Luo W, Liu C, Wu X, et al. 2013. High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-γ dysregulation of CD4+ T cells. Hepatology 57:1620-31
32. Kim G, Shinnakasu R, Saris CJ, Cheroutre H, Kronenberg M. 2013. A novel role for IL-27 in mediating the survival of activated mouse CD4 T lymphocytes. J. Immunol. 190:1510-18
33. Devergne O, HummelM, Koeppen H, Le Beau MM, Nathnson EC, et al. 1996. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J. Virol. 70:1143-53
34. Devergne O, Birkenbach M, Kieff E. 1997. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. PNAS 94:12041-46
35. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566-69
36. Crabe S, Guay-Giroux A, Tormo AJ, Duluc D, Lissilaa R, et al. 2009. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulatingNKandTcell activities requiring IL-6R for signaling. J. Immunol. 183:7692-702
37. Wang RX, Yu CR, Mahdi RM, Egwuagu CE. 2012. Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells. J. Biol. Chem. 287:36012-21
38. Stumhofer JS, Tait ED, Quinn WJ III, Hosken N, Spudy B, et al. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol. 11:1119-26
39. Shimozato O, Sato A, Kawamura K, Chiyo M, Ma G, et al. 2009. The secreted form of p28 subunit of interleukin (IL)-27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses. Immunology 128:e816-25
40. Dibra D, Cutrera J, Xia X, Kallakury B, Mishra L, Li S. 2012. Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology 55:1204-14
41. Rousseau F, Basset L, Froger J, Dinguirard N, Chevalier S, Gascan H. 2010. IL-27 structural analysis demonstrates similarities with ciliary neurotrophic factor (CNTF) and leads to the identification of antagonistic variants. PNAS 107:19420-25
42. Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, et al. 2013. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J. Biol. Chem. 288:4346-54
43. Hall AO, Silver JS, Hunter CA. 2012. The immunobiology of IL-27. Adv. Immunol. 115:1-44
44. CurranMA, Geiger TL,MontalvoW,Kim M, Reiner SL, et al. 2013. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J. Exp. Med. 210:743-55
45. Dibra D, Cutrera JJ, Li S. 2012. Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30. J. Immunol. 188:3709-15
46. van Seventer JM, Nagai T, van Seventer GA. 2002. Interferon-β differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells. J. Neuroimmunol. 133:60-71
47. Remoli ME,GafaV,Giacomini E, SeveraM, Lande R, Coccia EM. 2007. IFN-βmodulates the response to TLR stimulation in human DC: Involvement of IFN regulatory factor-1 (IRF-1) in IL-27 gene expression. Eur. J. Immunol. 37:3499-508
48. Molle C, Nguyen M, Flamand V, Renneson J, Trottein F, et al. 2007. IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor. J. Immunol. 178:7607-15
49. Liu J, Guan X,Ma X. 2007. Regulation of IL-27 p28 gene expression in macrophages through MyD88-and interferon-γ-mediated pathways. J. Exp. Med. 204:141-52
50. Pirhonen J, Siren J, Julkunen I,Matikainen S. 2007. IFN-αregulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J. Leukoc. Biol. 82:1185-92
51. Bosmann M, Ward PA. 2013. Modulation of inflammation by interleukin-27. J. Leukoc. Biol. 94:1159-65
52. Schnurr M, ToyT, Shin A,WagnerM,Cebon J, MaraskovskyE. 2005. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 105:1582-89
53. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J. 2005. C5a negatively regulates Toll-like receptor 4-induced immune responses. Immunity 22:415-26
54. la Sala A, Gadina M, Kelsall BL. 2005. Gi-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J. Immunol. 175:2994-99
55. Bosmann M, Haggadone MD, Hemmila MR, Zetoune FS, Sarma JV, Ward PA. 2012. Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages. J. Immunol. 188:5086-93
56. Pawaria S, Ramani K, Maers K, Liu Y, Kane LP, et al. 2014. Complement component C5a permits the coexistence of pathogenic Th17 Cells and type I IFN in lupus. J. Immunol. 193:3179-80
57. LambertQT, Pradhan A, Roll JD, Reuther GW. 2011. Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity. Biochem. J. 438:155-64
58. Pradhan A, Lambert QT, Reuther GW. 2007. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. PNAS 104:18502-7
59. Sprecher CA, Grant FJ, Baumgartner JW, Presnell SR, Schrader SK, et al. 1998. Cloning and characterization of a novel class I cytokine receptor. Biochem. Biophys. Res. Commun. 246:82-90
60. Perona-Wright G, Kohlmeier JE, Bassity E, Freitas TC, Mohrs K, et al. 2012. Persistent loss of IL-27 responsiveness in CD8+ memory T cells abrogates IL-10 expression in a recall response. PNAS 109:18535-40
61. HashimotoY,KuritaM,Aiso S,Nishimoto I, MatsuokaM. 2009. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor α/WSX-1/gp130. Mol. Biol. Cell 20:2864-73
62. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, et al. 2012. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 13:290-99
63. WangRX,YuCR, Dambuza IM, MahdiRM, DolinskaMB, et al. 2014. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20:633-41
64. Dietrich C, Candon S, Ruemmele FM, Devergne O. 2014. A soluble form of IL-27Rαis a natural IL-27 antagonist. J. Immunol. 192:5382-89
65. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, et al. 2012. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484:529-33
66. Villarino AV, Stumhofer JS, Saris CJ, Kastelein RA, de Sauvage FJ, Hunter CA. 2006. IL-27 limits IL-2 production during Th1 differentiation. J. Immunol. 176:237-47
67. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, et al. 2006. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7:937-45
68. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, et al. 2007. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin. Nat. Immunol. 8:1363-71
69. Hall AO, Beiting DP, Tato C, John B, Oldenhove G, et al. 2012. The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 37:511-23
70. Young A, Linehan E, Hams E, O'Hara Hall AC, McClurg A, et al. 2012. Cutting Edge: suppression of GM-CSF expression in murine and human T cells by IL-27. J. Immunol. 189:2079-83
71. Bancroft AJ, Humphreys NE, Worthington JJ, Yoshida H, Grencis RK. 2004. WSX-1: a key role in induction of chronic intestinal nematode infection. J. Immunol. 172:7635-41
72. Villarino AV, Artis D, Bezbradica JS, Miller O, Saris CJ, et al. 2008. IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD. Int. Immunol. 20:739-52
73. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, et al. 2003. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198:1951-57
74. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, et al. 2012. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13:991-99
75. El-behi M, Ciric B, Yu S, Zhang GX, Fitzgerald DC, Rostami A. 2009. Differential effect of IL-27 on developing versus committed Th17 cells. J. Immunol. 183:4957-67
76. Murugaiyan G, Mittal A, Lopez-Diego R, Maier LM, Anderson DE,Weiner HL. 2009. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J. Immunol. 183:2435-43
77. Liu H, Rohowsky-Kochan C. 2011. Interleukin-27-mediated suppression of human Th17 cells is associated with activation of STAT1 and suppressor of cytokine signaling protein. J. Interferon Cytokine Res. 31:459-69
78. Villarino AV, Gallo E, Abbas AK. 2010. STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and-independent mechanisms. J. Immunol. 185:6461-71
79. Hirahara K, Ghoreschi K, Yang XP, Takahashi H, Laurence A, et al. 2012. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 36:1017-30
80. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-87
81. Topalian SL, Drake CG, Pardoll DM. 2012. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24:207-12
82. Couper KN, Blount DG, Riley EM. 2008. IL-10: the master regulator of immunity to infection. J. Immunol. 180:5771-77
83. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, et al. 1996. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses. J. Clin. Investig. 98:1010-20
84. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, et al. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8:1380-89
85. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, et al. 2007. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8:1372-79
86. Freitas doRosario AP,LambT, Spence P, StephensR,LangA, et al. 2012. IL-27 promotes IL-10 production by effector Th1 CD4+ T cells: a critical mechanism for protection from severe immunopathology during malaria infection. J. Immunol. 188:1178-90
87. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, et al. 2011. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J. Immunol. 186:3977-85
88. Wang H, Meng R, Li Z, Yang B, LiuY, et al. 2011. IL-27 induces the differentiation ofTr1-like cells from human naive CD4+ T cells via the phosphorylation of STAT1 and STAT3. Immunol. Lett. 136:21-28
89. Pot C, Jin H, Awasthi A, Liu SM, Lai CY, et al. 2009. Cutting Edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 183:797-801
90. Xu J, Yang Y, Qiu G, Lal G, Wu Z, et al. 2009. c-Maf regulates IL-10 expression during Th17 polarization. J. Immunol. 182:6226-36
91. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, et al. 2010. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11:854-61
92. Stumhofer JS, Silver JS, Hunter CA. 2013. IL-21 is required for optimal antibody production and T cell responses during chronic Toxoplasma gondii infection. PLOS ONE 8:e62889
93. Wu C, Pot C, Apetoh L, Thalhamer T, Zhu B, et al. 2013. Metallothioneins negatively regulate IL-27-induced type 1 regulatory T-cell differentiation. PNAS 110:7802-7
94. Seita J, Asakawa M, Ooehara J, Takayanagi S, Morita Y, et al. 2008. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 111:1903-12
95. Wojno ED, Hosken N, Stumhofer JS, O'Hara AC, Mauldin E, et al. 2011. A role for IL-27 in limiting T regulatory cell populations. J. Immunol. 187:266-73
96. Neufert C, Becker C,Wirtz S, FantiniMC, Weigmann B, et al. 2007. IL-27 controls the development of inducible regulatoryTcells andTh17 cells via differential effects on STAT1. Eur. J. Immunol. 37:1809-16
97. HuberM, Steinwald V, Guralnik A, Brustle A, Kleemann P, et al. 2008. IL-27 inhibits the development of regulatory T cells via STAT3. Int. Immunol. 20:223-34
98. Cox JH, Kljavin NM, Ramamoorthi N, Diehl L, Batten M, Ghilardi N. 2011. IL-27 promotes T celldependent colitis through multiple mechanisms. J. Exp. Med. 208:115-23
99. Villarino AV, Larkin J 3rd, Saris CJ, Caton AJ, Lucas S, et al. 2005. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J. Immunol. 174:7684-91
100. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. 2009. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10:595-602
101. Oldenhove G, Bouladoux N, Wohlfert EA, Hall JA, Chou D, et al. 2009. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31:772-86
102. Moon SJ, Park JS, Heo YJ, Kang CM, Kim EK, et al. 2013. In vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis. Exp. Mol. Med. 45:e46
103. Owaki T, Asakawa M, Fukai F, Mizuguchi J, Yoshimoto T. 2006. IL-27 Induces Th1 differentiation via p38 MAPK/T-bet-and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 177:7579-87
104. Liao JJ, Huang MC, Goetzl EJ. 2007. Cutting Edge: alternative signaling of Th17 cell development by sphingosine 1-phosphate. J. Immunol. 178:5425-28
105. Gwyer Findlay E, Villegas-Mendez A, de Souza JB, Inkson CA, Shaw TN, et al. 2013. IL-27 receptor signaling regulates CD4+ T cell chemotactic responses during infection. J. Immunol. 190:4553-61
106. Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, Yoshimoto T. 2005. Augmentation of effector CD8+T cell generation with enhanced granzyme B expression by IL-27. J. Immunol. 175:1686-93
107. Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. 2011. IL-27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur. J. Immunol. 41:47-59
108. Brender C, Tannahill GM, Jenkins BJ, Fletcher J, Columbus R, et al. 2007. Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 8. Blood 110:2528-36
109. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, et al. 2005. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 115:437-42
110. ChiyoM, ShimozatoO, IizasaT, Fujisawa T, TagawaM. 2004. Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. Anticancer Res. 24:3763-67
111. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, et al. 2004. Potent antitumor activity of interleukin-27. Cancer Res. 64:1152-56
112. Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, et al. 2009. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182:4328-38
113. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, et al. 2004. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol. 173:7170-82
114. Shinozaki Y,Wang S, Miyazaki Y, Miyazaki K, Yamada H, et al. 2009. Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int. J. Cancer 124:1372-78
115. Mayer KD, Mohrs K, ReileyW,Wittmer S, Kohlmeier JE, et al. 2008. Cutting Edge: T-bet and IL-27R are critical for in vivo IFN-γproduction by CD8 T cells during infection. J. Immunol. 180:693-97
116. Pennock ND,Gapin L, Kedl RM. 2014. IL-27 is required for shaping the magnitude, affinity distribution and memory of T cells responding to subunit immunization. PNAS 111:16472-77
117. Biswas PS, Pedicord V, Ploss A, Menet E, Leiner I, Pamer EG. 2007. Pathogen-specific CD8 T cell responses are directly inhibited by IL-10. J. Immunol. 179:4520-28
118. Foulds KE, Rotte MJ, Seder RA. 2006. IL-10 is required for optimal CD8 T cell memory following Listeria monocytogenes infection. J. Immunol. 177:2565-74
119. Villarino AV, Tato CM, Stumhofer JS, Yao Z, Cui YK, et al. 2007. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J. Exp. Med. 204:65-71
120. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-46
121. Villarino AV, Huang E, Hunter CA. 2004. Understanding the pro-and anti-inflammatory properties of IL-27. J. Immunol. 173:715-20
122. Miyazaki Y, Inoue H, MatsumuraM,Matsumoto K, Nakano T, et al. 2005. Exacerbation of experimental allergic asthma by augmented Th2 responses inWSX-1-deficient mice. J. Immunol. 175:2401-7
123. Artis D, Johnson LM, Joyce K, Saris C, Villarino A, et al. 2004. Cutting Edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J. Immunol. 172:4672-75
124. Miyazaki Y, Inoue H, MatsumuraM,Matsumoto K, Nakano T, et al. 2005. Exacerbation of experimental allergic asthma by augmented Th2 responses inWSX-1-deficient mice. J. Immunol. 175:2401-7
125. Harker JA, Lewis GM, Mack L, Zuniga EI. 2012. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334:825-29
126. Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, et al. 2009. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat. Immunol. 10:167-75
127. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, et al. 2008. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29:138-49
128. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, et al. 2002. A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630-34
129. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173:5361-71
130. Cao Y, Doodes PD, Glant TT, Finnegan A. 2008. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J. Immunol. 180:922-30
131. Batten M, Ramamoorthi N, Kljavin NM, Ma CS, Cox JH, et al. 2010. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J. Exp. Med. 207:2895-906
132. Harker JA, Dolgoter A, Zuniga EI. 2013. Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4+ T cell responses and viral control during chronic infection. Immunity 39:548-59
133. Ballesteros-Tato A, Leon B, Graf BA, Moquin A, Adams PS, et al. 2012. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36:847-56
134. Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S. 2012. STAT5 is a potent negative regulator of TFH cell differentiation. J. Exp. Med. 209:243-50
135. Nurieva RI, Podd A, Chen Y, Alekseev AM, Yu M, et al. 2012. STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J. Biol. Chem. 287:11234-39
136. Boumendjel A, Tawk L, de Waal Malefijt R, Boulay V, Yssel H, Pène J. 2006. IL-27 induces the production of IgG1 by human B cells. Eur. Cytokine Netw. 17:281-89
137. Yoshimoto T, Okada K, Morishima N, Kamiya S, Owaki T, et al. 2004. Induction of IgG2a class switching in B cells by IL-27. J. Immunol. 173:2479-85
138. Larousserie F, Charlot P, Bardel E, Froger J, Kastelein RA, Devergne O. 2006. Differential effects of IL-27 on human B cell subsets. J. Immunol. 176:5890-97
139. Charlot-Rabiega P, Bardel E, Dietrich C, Kastelein R, Devergne O. 2011. Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells. J. Biol. Chem. 286:27350-62
140. Cocco C, Morandi F, Airoldi I. 2011. Interleukin-27 and interleukin-23 modulate human plasmacell functions. J. Leukoc. Biol. 89:729-34
141. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, et al. 2009. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10:778-85
142. Dibra D, Cutrera JJ, Xia X, Birkenbach MP, Li S. 2009. Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res. 69:5505-13
143. Dibra D, Cutrera J, Xia X, Li S. 2011. WSX1 expression in tumors induces immune tolerance via suppression of effector immune cells. PLOS ONE 6:e19072
144. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, et al. 2008. Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180:6527-35
145. Dong S, Zhang X, He Y, Xu F, Li D, et al. 2013. Synergy of IL-27 and TNF-αin regulating CXCL10 expression in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 48:518-30
146. Hu S, Wong CK, LamCW. 2011. Activation of eosinophils by IL-12 family cytokine IL-27: implications of the pleiotropic roles of IL-27 in allergic responses. Immunobiology 216:54-65
147. Kido M, Takeuchi S, Sugiyama N, Esaki H, Nakashima H, et al. 2011. T cell-specific overexpression of interleukin-27 receptor αsubunit (WSX-1) prevents spontaneous skin inflammation in MRL/lpr mice. Br. J. Dermatol. 164:1214-20
148. Wirtz S,Tubbe I, Galle PR, Schild HJ,Birkenbach M, et al. 2006. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin. J. Exp. Med. 203:1875-81
149. de Almeida Nagata DE, Demoor T, Ptaschinski C, Ting HA, Jang S, et al. 2014. IL-27R-mediated regulation of IL-17 controls the development of respiratory syncytial virus-associated pathogenesis. Am. J. Pathol. 184:1807-18
150. Zeng R, ZhangH,Hai Y, Cui Y,Wei L, et al. 2012. Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses. J. Virol. 86:4505-17
151. Passos ST, Silver JS, O'Hara AC, Sehy D, Stumhofer JS, Hunter CA. 2010. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J. Immunol. 184:1776-83
152. Cao J,WangD,Xu F,GongY,WangH, et al. 2014. Activation of IL-27 signalling promotes development of postinfluenza pneumococcal pneumonia. EMBO Mol. Med. 6:120-40
153. Laroni A, Gandhi R, Beynon V, Weiner HL. 2011. IL-27 imparts immunoregulatory function to human NK cell subsets. PLOS ONE 6:e26173
154. Wei J, Xia S, Sun H, Zhang S, Wang J, et al. 2013. Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation ofNKandNKTcells. J. Immunol. 191:500-8
155. Wang S, Miyazaki Y, Shinozaki Y, Yoshida H. 2007. Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1(IL-27R) deficiency. J. Immunol. 179:6421-28
156. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, et al. 2013. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat. Immunol. 14:1054-63
157. Karakhanova S, Bedke T, Enk AH, MahnkeK. 2011. IL-27 rendersDCimmunosuppressive by induction of B7-H1. J. Leukoc. Biol. 89:837-45
158. Morandi F, Di Carlo E, Ferrone S, Petretto A, Pistoia V, Airoldi I. 2014. IL-27 in human secondary lymphoid organs attractsmyeloid dendritic cells and impairsHLA class I-restricted antigen presentation. J. Immunol. 192:2634-42
159. Kalliolias GD, Ivashkiv LB. 2008. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J. Immunol. 180:6325-33
160. Iyer SS, Ghaffari AA, Cheng G. 2010. Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J. Immunol. 185:6599-607
161. Imamichi T, Yang J,Huang DW, Brann TW, Fullmer BA, et al. 2008. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. AIDS 22:39-45
162. DaiL,Lidie KB,ChenQ,Adelsberger JW,Zheng X, et al. 2013. IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. J. Exp. Med. 210:517-34
163. Cao Y, Zhang R, Zhang W, Zhu C, Yu Y, et al. 2014. IL-27, a cytokine, and IFN-λ1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J. Immunol. 192:691-703
164. Liu L, Cao Z, Chen J, Li R, Cao Y, et al. 2012. Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase A signaling. J. Biol. Chem. 287:11899-910
165. Swaminathan S,HuX,Zheng X, KrigaY, Shetty J, et al. 2013. Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties. Biochem. Biophys. Res. Commun. 434:228-34
166. Kalliolias GD, Gordon RA, Ivashkiv LB. 2010. Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J. Immunol. 185:7047-56
167. Jafarzadeh A, Nemati M, RezayatiMT. 2011. Serum levels of interleukin (IL)-27 in patientswith ischemic heart disease. Cytokine 56:153-56
168. Wong HR, Cvijanovich NZ, Hall M, Allen GL, Thomas NJ, et al. 2012. Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit. Care 16:R213
169. WongHR, Lindsell CJ,Lahni P, HartKW,Gibot S. 2013. Interleukin 27 as a sepsis diagnostic biomarker in critically ill adults. Shock 40:382-86
170. Du HZ, Wang Q, Ji J, Shen BM, Wei SC, et al. 2013. Expression of IL-27, Th1 and Th17 in patients with aplastic anemia. J. Clin. Immunol. 33:436-45
171. Lin TT, Lu J, Qi CY,YuanL,LiXL, et al. 2014. Elevated serum level of IL-27 andVEGFin patients with ankylosing spondylitis and associate with disease activity. Clin. Exp. Med. In press. doi: 10.1007/s10238-014-0281-x
172. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, et al. 2007. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13:711-18
173. Karp CL, el-Safi SH,WynnTA, SattiMM,KordofaniAM, et al. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-γ. J. Clin. Investig. 91:1644-48
174. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, et al. 2011. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J. Infect. Dis. 204:1134-37
175. Ayimba E, Hegewald J, Segbena AY, Gantin RG, Lechner CJ, et al. 2011. Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria. Clin. Exp. Immunol. 166:218-26
176. LiuL,Okada S, Kong XF,Kreins AY, Cypowyj S, et al. 2011. Gain-of-function human STAT1mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 208:1635-48
177. Sonobe Y, Yawata I, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. 2005. Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations. Brain Res. 1040:202-7
178. Fitzgerald DC, Ciric B, Touil T, Harle H, Grammatikopolou J, et al. 2007. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 179:3268-75
179. Murugaiyan G, Beynon V, Pires Da Cunha A, Joller N,Weiner HL. 2012. IFN-γlimits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J. Immunol. 189:5277-83
180. Pirhonen J, Siren J, Julkunen I,Matikainen S. 2007. IFN-αregulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J. Leukoc. Biol. 82:1185-92
181. Guo B, Chang EY, Cheng G. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Investig. 118:1680-90
182. Shinohara ML, Kim JH, Garcia VA, Cantor H. 2008. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 29:68-78
183. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, et al. 2011. IL-27 mediates the response to IFN-βtherapy inmultiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun. 25:1170-81
184. Niedbala W, Cai B,Wei X, Patakas A, Leung BP, et al. 2008. Interleukin-27 attenuates collagen-induced arthritis. Ann. Rheum. Dis. 67:1474-79
185. Pickens SR, Chamberlain ND, Volin MV, Mandelin AM 2nd, Agrawal H, et al. 2011. Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum. 63:2289-98
186. Paradowska-Gorycka A, Raszkiewicz B, Jurkowska M, Felis-Giemza A, Romanowska-Prochnicka K, et al. 2014. Association of single nucleotide polymorphisms in the IL27 gene with rheumatoid arthritis. Scand. J. Immunol. 80:298-305
187. Tanida S, Yoshitomi H, Ishikawa M, Kasahara T, Murata K, et al. 2011. IL-27-producing CD14+ cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration. Cytokine 55:237-44
188. Lee BH, CarcamoWC, Chiorini JA, Peck AB,Nguyen CQ. 2012. Gene therapy using IL-27 ameliorates Sjogren's syndrome-like autoimmune exocrinopathy. Arthritis Res. Ther. 14:R172
189. Xia L, ShenH, Zhao L, Lu J. 2012. Elevated levels of interleukin-27 in patients with Sjogren's syndrome. Scand. J. Rheumatol. 41:73-74
190. Kido M, Takeuchi S, Sugiyama N, Esaki H, Nakashima H, et al. 2011. T cell-specific overexpression of interleukin-27 receptor αsubunit (WSX-1) prevents spontaneous skin inflammation in MRL/lpr mice. Br. J. Dermatol. 164:1214-34
191. Sugiyama N, Nakashima H, Yoshimura T, Sadanaga A, Shimizu S, et al. 2008. Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor α(WSX-1). Ann. Rheum. Dis. 67:1461-68
192. Igawa T, Nakashima H, Sadanaga A, Masutani K, Miyake K, et al. 2009. Deficiency in EBV-induced gene 3 (EBI3) in MRL/lpr mice results in pathological alteration of autoimmune glomerulonephritis and sialadenitis. Mod. Rheumatol. 19:33-41
193. Banchereau J, PascualV. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25:383-92
194. Li TT, Zhang T, Chen GM, Zhu QQ, Tao JH, et al. 2010. Low level of serum interleukin 27 in patients with systemic lupus erythematosus. J. Investig. Med. 58:737-39
195. Wittmann M, Zeitvogel J,Wang D,Werfel T. 2009. IL-27 is expressed in chronic human eczematous skin lesions and stimulates human keratinocytes. J. Allergy Clin. Immunol. 124:81-89
196. Wittmann M, Doble R, Bachmann M, Pfeilschifter J, Werfel T, Muhl H. 2012. IL-27 regulates IL-18 binding protein in skin resident cells. PLOS ONE 7:e38751
197. Kanda N, Watanabe S. 2008. IL-12, IL-23, and IL-27 enhance human β-defensin-2 production in human keratinocytes. Eur. J. Immunol. 38:1287-96
198. Shibata S, Tada Y, Asano Y, Yanaba K, Sugaya M, et al. 2012. IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions. J. Investig. Dermatol. 133:479-88
199. Shibata S, Tada Y, KandaN,Nashiro K, Kamata M, et al. 2010. Possible roles of IL-27 in the pathogenesis of psoriasis. J. Investig. Dermatol. 130:1034-39
200. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, et al. 2011. Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Ann. Rheum. Dis. 70:194-200
201. Honda K, Nakamura K,Matsui N, Takahashi M, Kitamura Y, et al. 2005. T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis. Inflamm. Bowel Dis. 11:1044-52
202. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, et al. 2011. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am. J. Physiol. Gastrointest. Liver Physiol. 300:G568-76
203. Diegelmann J, Olszak T, Göke B, Blumberg RS, Brand S. 2011. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. J. Biol. Chem. 287:286-98
204. Li CS, Zhang Q, Lee KJ, Cho SW, Lee KM, et al. 2009. Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. J. Gastroenterol. Hepatol. 24:1692-96
205. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, et al. 2009. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat. Genet. 41:1335-40
206. Dann SM,LeC,ChoudhuryBK, LiuH, SaldarriagaO, et al. 2014. Attenuation of intestinal inflammation in interleukin-10-deficient mice infected with Citrobacter rodentium. Infect. Immun. 82:1949-58
207. Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, et al. 2014. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146:210-21.e13
208. Fujita H, Teng A, Nozawa R, Takamoto-Matsui Y, Katagiri-Matsumura H, et al. 2009. Production of both IL-27 and IFN-γ after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model. J. Immunol. 183:254-60
209. Dokmeci E, Xu L, Robinson E, Golubets K, Bottomly K, Herrick CA. 2011. EBI3 deficiency leads to diminished T helper type 1 and increased T helper type 2 mediated airway inflammation. Immunology 132:559-66
210. Li JJ, Wang W, Baines KJ, Bowden NA, Hansbro PM, et al. 2010. IL-27/IFN-γ induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages. J. Immunol. 185:4401-9
211. Cao J,Wong CK, Yin Y, Lam CW. 2010. Activation of human bronchial epithelial cells by inflammatory cytokines IL-27 and TNF-α: implications for immunopathophysiology of airway inflammation. J. Cell. Physiol. 223:788-97
212. Cao J, Zhang L, Li D, Xu F, Huang S, et al. 2012. IL-27 is elevated in patients with COPD and patients with pulmonary TB and induces human bronchial epithelial cells to produce CXCL10. Chest 141:121-30
213. Larousserie F, Pflanz S, Coulomb-L'Hermine A, Brousse N, Kastelein R,DevergneO. 2004. Expression of IL-27 in human Th1-associated granulomatous diseases. J. Pathol. 202:164-71
214. Chae SC, Li CS, Kim KM, Yang JY, Zhang Q, et al. 2007. Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J. Hum. Genet. 52:355-61
215. Huang N, Liu L, Wang XZ, Liu D, Yin SY, Yang XD. 2008. Association of interleukin (IL)-12 and IL-27 gene polymorphisms with chronic obstructive pulmonary disease in a Chinese population. DNA Cell Biol. 27:527-31
216. Shen Y, Yuan XD, Hu D, Ke X, Wang XQ, et al. 2014. Association between Interleukin-27 gene polymorphisms and susceptibility to allergic rhinitis. Hum. Immunol. 75:991-95
217. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, et al. 2006. IL-23 promotes tumour incidence and growth. Nature 442:461-65
218. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, et al. 2006. Antiangiogenic and antitumor activities of IL-27. J. Immunol. 176:7317-24
219. Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, et al. 2013. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J. Exp. Clin. Cancer Res. 32:97
220. Nielsen SR, Hammer T, Gibson J, Pepper MS, Nisato RE, et al. 2013. IL-27 inhibits lymphatic endothelial cell proliferation by STAT1-regulated gene expression. Microcirculation 20:555-64
221. Canale S, Cocco C, Frasson C, Seganfreddo E, Di Carlo E, et al. 2011. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 25:1815-24
222. Natividad KD, Junankar SR, Mohd Redzwan N, Nair R, Wirasinha RC, et al. 2013. Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLOS ONE 8:e57469
223. Lu D, Zhou X, Yao L, Liu C, Jin F,Wu Y. 2014. Clinical implications of the interleukin 27 serum level in breast cancer. J. Investig. Med. 62:627-31
224. Ho MY, Leu SJ, Sun GH,Tao MH,Tang SJ, SunKH. 2009. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J. Immunol. 183:6217-26
225. Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, et al. 2012. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/-mice. Clin. Cancer Res. 18:1630-40
226. Koltsova EK, Kim G, Lloyd KM, Saris CJ, von Vietinghoff S, et al. 2012. Interleukin-27 receptor limits atherosclerosis in Ldlr-/-mice. Circ. Res. 111:1274-85
227. Hirase T, Hara H, Miyazaki Y, Ide N, Nishimoto-Hazuku A, et al. 2013. Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice. Am. J. Physiol. Heart Circ. Physiol. 305:H420-29
228. Fujimoto H, Hirase T, Miyazaki Y, Hara H, Ide-Iwata N, et al. 2011. IL-27 inhibits hyperglycemia and pancreatic islet inflammation induced by streptozotocin in mice. Am. J. Pathol. 179:2327-36
229. Wang R, Han G,Wang J, Chen G, Xu R, et al. 2008. The pathogenic role of interleukin-27 in autoimmune diabetes. Cell. Mol. Life Sci. 65:3851-60